Stockscreener 앱 받기
2.7345
2.69%
-0.0755
Jaguar Health Inc 주식(JAGX)의 최신 뉴스
Jaguar Health, Inc. Files 8-K Report on July 1, 2026 – Key Company Information & SEC Disclosure Details - Minichart
Enterprise value to revenue forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health (JAGX) completes Series O preferred stock conversion to common shares - Stock Titan
JAGXJaguar Health Inc Latest SEC Filings - Finviz
Jaguar Health Company Profile & Introduction - Moomoo
Jaguar Health (JAGX) Showcases Crofelemer Data at ESPGHAN Conference - GuruFocus
Jaguar Health reports crofelemer data for rare pediatric diseases - Investing.com
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF) - ACCESS Newswire
Jaguar Health says crofelemer cut one child's support needs by 48% - Stock Titan
Enterprise value to EBIT forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Price to earnings forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Price to book forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Enterprise value to revenue forward of Jaguar Health, Inc. – BOATS:JAGX - TradingView
Jaguar Health shares after reverse split, small-cap biotech stock in the OTC market spotlight - AD HOC NEWS
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - GlobeNewswire Inc.
Enterprise value to EBITDA forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Inc (JAGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBITDA forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health (JAGX) Announces Conversion of Series O Convertibl - GuruFocus
Jaguar Health Converts Series O Preferred Stock; Advances Crofelemer Program for Rare Intestinal Failure Diseases - Minichart
Series O preferred conversion at Jaguar Health (NASDAQ: JAGX) - Stock Titan
Price to sales forward of Jaguar Health, Inc. – NASDAQ:JAGX - TradingView
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend - ACCESS Newswire
Jaguar Health's one-time stock dividend converts into 3.209 shares - Stock Titan
Enterprise value to EBIT forward of Jaguar Health, Inc. – GETTEX:1JA1 - TradingView
Jaguar Health Inc (JAGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jaguar Health (JAGX) Submits New Drug Application for Canalevia-CA1 - GuruFocus
Jaguar Health submits drug application for dog diarrhea treatment By Investing.com - Investing.com Australia
Jaguar Health submits drug application for dog diarrhea treatment - Investing.com UK
Jaguar Health explores strategic options, shares react ahead of Nasdaq investor forum - AD HOC NEWS
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - ACCESS Newswire
Jaguar Health seeks full FDA approval for dog diarrhea drug - Stock Titan
Jaguar Health Explores Strategic Alternatives Ahead of NDA Filing for Crofelemer Rare Intestinal Failure Drug - Minichart
Jaguar Health (NASDAQ: JAGX) updates release on strategic alternatives - Stock Titan
Jaguar Health (JAGX) Explores Strategic Alternatives for Stockho - GuruFocus
Jaguar Health Explores Strategic Alternatives Ahead of NDA for Rare Intestinal Failure Drug Crofelemer in $1.1B Market 1 – Minichart - Minichart
Jaguar Health reviews strategic alternatives ahead of Crofelemer NDA filing - MSN
Jaguar Health explores strategic alternatives to maximize value By Investing.com - Investing.com South Africa
Jaguar Health explores strategic alternatives to maximize value - Investing.com
Form 8K Jaguar Health Inc For: 22 June By Investing.com - Investing.com Nigeria
Jaguar Health launches strategic review aligned with targeted NDA for crofelemer - TradingView
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program - ACCESS Newswire
Jaguar Health starts strategic review as crofelemer NDA work nears - Stock Titan
Jaguar Health Inc (JAGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention - ACCESS Newswire
Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health - Florida Hospital News and Healthcare Report
Jaguar Health, Inc. Announces Material Definitive Agreements and Exchange with Streeterville Capital and Uptown Capital – SEC 8-K Filing Summary – Minichart - Minichart
JAGUAR HEALTH INC (JAGX) Stock Chart - ChartMill
Jaguar Health Amends Royalty Deals, Extends Note Maturity, and Executes Three Preferred-for-Common Exchanges - TradingView
Jaguar Health (NASDAQ: JAGX) updates royalty terms and debt, swaps preferred for common - Stock Titan
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health - ACCESS Newswire
Jaguar Health (JAGX) Reports Promising Preclinical Study Results - GuruFocus
Jaguar Health reports coca leaf extract prevented weight gain in mice - Investing.com
1.16%
0.48%
자본화:
|
볼륨(24시간):